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Participant experiences from chronic administration of a multivitamin versus
placebo on subjective health and wellbeing: a double-blind qualitative analysis of
a randomised controlled trial
Abstract
Background While many randomised controlled trials have been conducted on multivitamins, to our
knowledge no qualitative research exploring the subjective experience of taking a multivitamin during a
clinical trial has been reported. Methods Semi-structured and open-ended written questions were
incorporated into a 16-week double-blind, randomised, placebo-controlled, parallel groups trial of oncedaily multivitamin administration. At the final study visit (week 16), three open-ended questions were
posed to elucidate any positive, negative or unusual experiences from taking either the multivitamin or
matched placebo. Qualitative thematic analysis was undertaken by researchers who were blind as to
treatment condition of participants, and triangulation (independent analysis from three researchers) was
employed to ensure methodological rigour. Participant's experiences were categorised as "positive" or
"negative" and a Chi Square analysis was then applied to each of the experiential themes, to compare
experiences between the multivitamin and placebo groups, (subdividing the groups by gender). Usual
experiences were categorised and discussed separately. Results Of the 182 participants enrolled, 116
completed the study and qualitative data were available from 114 participants. Thematic analysis
revealed significant effects in favour of the multivitamin over placebo for participants experiencing
increased energy levels (p=.022) and enhanced mood (p=.027). The beneficial effect on energy levels was
particularly evident among female participants. A trend was found for participants reporting better sleep
in the multivitamin over placebo. The multivitamin and placebo groups did not significantly differ in
perceived positive or negative effects in areas relating to other aspects of mental function or physical
health. No significant negative effects were revealed, although there was a non-significant trend for more
people in the multivitamin group having minor digestive complaints. Conclusion This represents the first
documented qualitative investigation of participants' experience of chronic administration of a
multivitamin. Results uncovered a range of subjective beneficial effects that are consistent with
quantitative data from previously published randomised controlled trials examining the effects of
multivitamins and B vitamin complexes on mood and well-being.
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Participant experiences from chronic
administration of a multivitamin versus
placebo on subjective health and wellbeing:
a double-blind qualitative analysis of a randomised
controlled trial
Jerome Sarris1,2, Katherine H M Cox2*, David A Camfield2, Andrew Scholey2, Con Stough2, Erin Fogg2, Marni Kras2,
David J White2,3, Avni Sali4 and Andrew Pipingas2

Abstract
Background: While many randomised controlled trials have been conducted on multivitamins, to our knowledge
no qualitative research exploring the subjective experience of taking a multivitamin during a clinical trial has been
reported.
Methods: Semi-structured and open-ended written questions were incorporated into a 16-week double-blind,
randomised, placebo-controlled, parallel groups trial of once-daily multivitamin administration. At the final study
visit (week 16), three open-ended questions were posed to elucidate any positive, negative or unusual experiences
from taking either the multivitamin or matched placebo. Qualitative thematic analysis was undertaken by
researchers who were blind as to treatment condition of participants, and triangulation (independent analysis from
three researchers) was employed to ensure methodological rigour. Participant’s experiences were categorised as
“positive” or “negative” and a Chi Square analysis was then applied to each of the experiential themes, to compare
experiences between the multivitamin and placebo groups, (subdividing the groups by gender). Usual experiences
were categorised and discussed separately.
Results: Of the 182 participants enrolled, 116 completed the study and qualitative data were available from 114
participants. Thematic analysis revealed significant effects in favour of the multivitamin over placebo for participants
experiencing increased energy levels (p=.022) and enhanced mood (p=.027). The beneficial effect on energy levels
was particularly evident among female participants. A trend was found for participants reporting better sleep in the
multivitamin over placebo. The multivitamin and placebo groups did not significantly differ in perceived positive or
negative effects in areas relating to other aspects of mental function or physical health. No significant negative
effects were revealed, although there was a non-significant trend for more people in the multivitamin group having
minor digestive complaints.
(Continued on next page)
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Conclusion: This represents the first documented qualitative investigation of participants’ experience of chronic
administration of a multivitamin. Results uncovered a range of subjective beneficial effects that are consistent with
quantitative data from previously published randomised controlled trials examining the effects of multivitamins and
B vitamin complexes on mood and well-being.
Trial registration: Prior to commencement this trial was registered with the Australian New Zealand Clinical Trials
Registry (www.anzctr.org.au) ACTRN12611000092998
Keywords: Multivitamin, Mood, Energy, Cognition, Adverse reactions, Qualitative

Background
The use of multivitamin (MV) supplements has become
increasingly popular among the general public [1]. There
is growing literature to suggest that MV or multinutrient
supplementation may have cognitive and/or mood benefits in children [2] and across the adult life span [3-10].
There are a numerous ingredients commonly found in
MV and mineral supplements that may affect cognition
and mood. Low B vitamin levels have been linked to
increased levels of homocysteine, which can have a detrimental effect on cognition [11,12], and lowered levels of
Vitamin B12 and folic acid have been associated with
higher incidence of depression or depressed mood [13-15].
Vitamin C may improve cognition, as a result of central
antioxidant activity [16,17]. Vitamin D can improve mood
[18], and supplementation may promote general health
through its integral involvement in a vast number of biological processes [19]. Minerals such as zinc, magnesium
and calcium influence neurotransmitter systems and therefore play an important role in maintaining healthy cognitive function and mood [20-22]. Additionally, though often
present in small (and potentially sub-therapeutic) quantities in MVs, herbal ingredients such as Ginkgo biloba
and Panax ginseng may reduce stress and anxiety [23,24]
while Centella asiatica has exhibited mood enhancing
effects [25].
The Swisse Ultivite F1 multivitaminW (SMV) contains
a proprietary blend of vitamins at levels exceeding
recommended daily intakes (which are arguably low),
minerals, as well as low doses of a range of medicinal
herbs. Previous studies from our laboratory have identified beneficial effects of SMV use in older populations.
Harris et al. [7] found that an 8-week supplementation
with Men’s SMV in males aged 50–69 years was associated with a significant reduction in symptoms of depression and anxiety and an improvement in alertness
and general health, that were not seen in the placebo
group. The same treatment was associated with improvements in contextual recognition memory performance in men aged between 50 and 74 years who had a
sedentary lifestyle [10]. Macpherson et al. [26], also
showed that 16-week supplementation with a SMV formula designed for older women (50+ UltiviteW) was

associated with faster speed of spatial working memory
performance.
The present 16-week double-blind randomised controlled trial (RCT) sought to extend these findings to
younger individuals aged 20–50 years and to test once
daily Swisse Men’s and Women’s UltiviteW multinutrient supplements. The clinical trial assessed the effect of the SMV on cognition, and on psychological
attributes such as mood, stress, sleep, and energy levels.
The study also utilised a “mixed-methods” approach
employing both quantitative and qualitative methodological techniques (the quantitative analyses are reported
elsewhere). Qualitative measures may form the focus of
a study, or be part of a combined approach whereby a
qualitative component augments the quantitative mainstay of an RCT [27-29]. These measures can assist to
understand participants’ experiences of an intervention
in an RCT [27-29]. This approach can help to develop
hypotheses for future research, and may identify previously unknown therapeutic benefits or side-effects. To
our knowledge qualitative methodology has not previously been used in RCTs of MVs. It is important to note
that while there is a key difference between reductive
statistically-based quantitative research and exploratory
experiential qualitative research, in order to maintain
methodological rigour, it is possible to conduct qualitative research in a double-blinded manner, with neither
the participants nor the researchers who analyse the data
knowing which participants received the active or placebo intervention.
In this paper we present the qualitative component of
the study (analysed via quantitative methodology) which
explores participants personal experiences of being
chronically administered a MV compared to placebo.

Methods
Overview

Eligible consenting adults participated in a 16-week
double-blind RCT involving once daily administration of
SMV tablet or matching placebo. Participants attended
three testing sessions at the Centre for Human Psychopharmacology at Swinburne University in Melbourne, at
baseline, 8-weeks and 16-weeks, for the assessment of
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wellbeing, mood, stress and cognition. Potential biological mechanisms of action were also examined. The
study was granted ethical approval by the Swinburne
University of Technology Ethics Human Ethics Committee (SUHREC Project 2010/261) and was registered
with the Australian New Zealand Clinical Trials Registry (ANZCTR no: ACTRN12611000092998) prior to
commencement.
Participants

Recruitment was carried out from February to August
2011 and was facilitated via adverts in newspapers and
flyers, radio, television, and social media. Inclusion criteria required participants who were healthy, nonsmoking males and females aged 20 to 50 years who
were currently engaged in at least part-time employment
and/or undertaking a higher education or technical college course. They had no history of head injury or
stroke, psychiatric or neurologic conditions, heart disease or diabetes and had no present kidney, liver or
gastrointestinal conditions that might impair food metabolism. They were also free from any known or suspected food allergies. Individuals were ineligible to
participate if they were pregnant or taking any form of
herbal or vitamin supplement or over the counter or
prescription medications (with the exception of the oral
contraception pill).
Treatments, randomisation and blinding

The treatment received (depending on gender) was either Swisse Men’s Ultivite F1W/Swisse Women’s Ultivite
F1 W(SMV) or matching placebo. The contents of the
men’s and women’s SMV preparations are shown in
Tables 1 and 2 respectively. Both contain a blend of vitamins at levels exceeding recommended daily intakes
(RDI) [30] including B vitamins (e.g. Thiamin approx.
2500-4500% RDI, Riboflavin approx. 2300%-4545% RDI,
Niacin approx. 185%-355% RDI, Pantothenic acid
approx. 1070%-1700% adequate intake, B6 approx.
1900%-3165% RDI and B12 approx. 1250%-2080% RDI)
and vitamins C (approx. 365% RDI), D (100% RDI) and
E (approx. 330%-475% RDI), as well as minerals such as
calcium, magnesium, potassium and iron. They also contain a range of antioxidants and extracts equivalent to
approximately 2.6-3g of medicinal herbs including
Ginkgo biloba, Vitis vinifera, Silybum marianum and
Camellia sinensis. Though the two formulations are predominantly equivalent the amount of some nutrients
varies slightly, for example the women’s formula contains higher levels of calcium and iron, and there are a
small number of herbal or plant extracts unique to either preparation. The placebo tablets were the same size
and colour as the SMV tablets and contained starch and
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a small amount of riboflavin (2mg) designed to give a
similar smell and colouration of the urine.
Treatment randomisation was independently carried
out, separately for males and females, in blocks of four
by the supplier; Swisse Vitamins Pty Ltd. Treatments
were assigned a treatment identification number and
packaged in identical boxes containing 18 blister packs
of 7 tablets (18 x week supply). The extra 2-week supply
of tablets was included to ensure continuous treatment
in the event of late return visits and to aid in the assessment of treatment compliance. Following baseline assessment, randomised participants were provided with
the treatment and instructed to take one tablet daily
with, or immediately following breakfast for the next 16
weeks, and to bring all unused tablets to each study visit.
Data were unblinded only after all data were finalised
and preliminary analyses were complete.
Procedure

Participants attended a brief practice session during
which written consent was obtained, eligibility was confirmed and they were familiarised with all study measures. Demographic characteristics that may have
modified outcomes were recorded, including age, education and BMI and measures of trait anxiety (State-Trait
Anxiety Inventory) [31], depression (Beck Depression
Inventory – II) [32] and intelligence (WASI Matrix reasoning task) [33] were completed. Three testing sessions
were undertaken: at baseline, Week 8 and Week 16. As
this trial was concerned with chronic effects of supplementation, participants were asked to abstain from
taking their tablet on the morning of testing sessions.
This avoided any potentially confounding acute effects
that a single day’s treatment may have had on assessments and which could not have been differentiated
from the chronic effects of repeated and prolonged
supplementation.
Participants completed standardised assessments of
wellbeing, mood and stress, and a computerised cognitive test battery. Blood measures, cardiovascular function
and salivary cortisol levels were investigated as potential
mechanisms of action. In total, each testing session
lasted approximately 3 hours. A researcher from the
Centre of Human Psychopharmacology at Swinburne
University of Technology administered all tests. The
number of tablets returned was used to calculate total
treatment compliance, with participants being required
to be at least 80% compliant for inclusion of their data
in analyses.
Qualitative assessment component

In addition to mood, cognitive and biomarker assessments, at the conclusion of the final testing session
(week 16), participants were presented with three
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Table 1 Men’s SMV preparation contents

Table 1 Men’s SMV preparation contents (Continued)

Component

Daily dose

Oats

500mg

Betacarotene

5mg

Bilberry

25mg

Vitamin D3

200IU

Grape seed

1g

Vitamin E

50IU

St Mary's thistle

50mg

Vitamin B1

30mg

Korean ginseng

50mg

Vitamin B2

30mg

Ginkgo

100mg

Nicotinamide

30mg

Saw Palmetto

200mg

Vitamin B5

64.13mg

Green tea

20mg

Vitamin B6

24.68mg

Tomato

700mg

Vitamin B12

30mg

Biotin

50 mcg

Folic acid

500mcg

Vitamin C

165.2 mg

Choline bitartrate

25mg

Inositol

25mg

Citrus bioflavonoid extract

40mg

Tyrosine

1 mg

Lysine

50mg

Calcium

21mg

Magnesium

57.89mg

written, semi-structured, open-ended qualitative questions. Pre-study, a pilot form was constructed via a consensus between researchers, being tested on a sample of
colleagues for feedback on the utility of its format. In response to the feedback the form was slightly modified by
consolidating questions into three major areas of enquiry. For each question, participants were directed to
indicate whether or not they perceived any direct effects
from taking the tablets, and if so to describe their experience in as much detail as possible.
The questions were as follows:

Potassium

4mg

Iron

3mg

Chromium

6.2mcg

Manganese

1.2mg

Copper

28mcg

Iodine

50mcg

Zinc

6mg

Selenium

26mcg

Co-Enzyme Q10

1 mg

Spearmint oil

1.5mg

Parsley

10mg

Data analysis

Papaya

10mg

As this was a double-blind study neither the study
researchers or the participants were aware of what treatment the participant had been receiving. After the study
was completed and the data were available for analysis,
the question transcripts were read by two researchers
and coded according to a grounded theory approach to
data analysis. Initially, participants’ experiences were
separated into “positive” and “negative” effects. Following this, two major domains (mental/cognitive and physical) were categorised, within which many distinct
themes were identified via a thematic analytic approach.
Each reported experience was then coded under a theme
heading by the researchers in a blinded manner. The
themes were then submitted to researcher triangulation
(whereby the three researchers provided independent
readings of the written responses, with any divergences
of interpretation discussed until resolution is reached).

Lutein

200mcg

Celery

20mg

Astragalus

50mg

Buchu

10mg

Barberry

15mg

Gotu kola

50mg

Hawthorn

100mg

Horsetail

30mg

Fennel

15mg

Sarsparilla

50mg

Damiana

120mg

Ginger

5mg

Globe artichoke

50mg

1) “In the past month describe any positive effects (if
any) on your physical or mental health (mood, stress,
brain function) that you think may have occurred due
to taking the tablets.”
2) “In the past month describe any negative effects (if
any) on your physical or mental health (mood, stress,
brain function) that you think may have occurred due
to taking the tablets.”
3) “If apparent, please describe any unusual effects that
you think may have occurred from taking the tablets.”
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Table 2 Women’s SMV preparation contents

Table 2 Women’s SMV preparation contents (Continued)

Component

Daily dose

Bilberry

25mg

Betacarotene

5mg

Grape seed

1g

Vitamin D3

200IU

St Mary's thistle

50mg

Vitamin E

50IU

Ginkgo

5mg

Vitamin B1

50 mg

Green tea

20mg

Vitamin B2

50mg

Tomato

700mg

Nicotinamide

50 mg

Vitamin B5

68.7 mg

Vitamin B6

41.14 mg

Vitamin B12

50 mcg

Biotin

50 mcg

Folic acid

500mcg

To provide increased scientific rigour, a quantitative
analysis was performed to compare the frequency with
which themes were reported within treatment groups.
For each participant every theme was coded as having
been “reported” or “not reported”. Using this categorical
classification a Chi Square analysis was then conducted
for each theme, with significance set at a p <.05, while a
trend towards significance regarded as between p of .05
and .10. These analyses were then repeated separately
within genders.

Vitamin C

165.2 mg

Choline bitartrate

25mg

Inositol

25mg

Citrus bioflavonoid extract

40mg

Lysine

50mg

Calcium

42 mg

Results

Magnesium

47.16 mg

Sample

Potassium

2 mg

Iron

4.9 mg

Chromium

6.2mcg

A total of 182 participants were enrolled in the study, of
these 138 received treatment. An attrition rate of approximately 16% was observed, with 116 participants
completing the study (Figure 1). Qualitative data was
available from 114 participants, 59 from the placebo group
and 55 from the SMV group. A count of returned tablets
indicated that all participants satisfied the 80% compliance
requirement at their final visit. The characteristics of the
sample (Table 3) revealed that the mean age of participants was early 30s, they were educated and had higher
than average intelligence, low depression and anxiety
levels, and an average BMI (for adult Australians). The
two treatment groups did not differ significantly on any
examined demographic characteristic, either in the sample as a whole or when split by gender.

Manganese

1.6 mg

Copper

58 mcg

Iodine

50.46 mcg

Zinc

5 mg

Selenium

26mcg

Co-Enzyme Q10

1 mg

Spearmint oil

1.5mg

Parsley

10mg

Papaya

10mg

Lutein

200mcg

Celery

20mg

Astragalus

50mg

Siberian Ginseng

25 mg

Bearberry

25mg

Gotu kola

10 mg

Hawthorn

30 mg

Horsetail

30mg

Fennel

15mg

Overview of qualitative data

The qualitative data were divided into “Positive Effects”
or “Negative Effects” and coded into four primary
domains, in addition to supplementary analysis of any
unusual experiences. A total of 21 further emergent
themes were found and coded under these main
domains (see Table 4). Examples of participants’ experiences are detailed below. Statements are provided that
best represent the themes revealed from qualitative analysis. As a result, some participants’ responses are not
included, while others are quoted more than once.

Chamomile

15 mg

Licorice

10 mg

Ginger

15mg

Globe artichoke

50mg

Summary of positive and negative experiences

Oats

500mg

In response to the question posed to participants about
any positive effects, the majority of participants (60.0%)
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Phone screened (n=253)
Excluded (n=71)
Ineligible: 24
Declined: 47
Screening/Training Session
(n=182)

Randomised (n= 138)

Baseline - Mul vitamin
(n=68)

Excluded (n=44)
Ineligible: 14
Withdrew Consent: 23
Lost to follow-up: 7

Baseline -Placebo
(n=70)

Withdrew Consent: 7
Lost to follow-up: 1

Withdrew Consent: 2
Lost to follow-up: 5
8 weeks - Mul vitamin
(n=60)

8 Weeks -Placebo
(n=63)
Withdrew Consent: 2
Lost to follow-up: 1

Withdrew Consent: 4
16 Weeks - Mul vitamin
(n=56*)

16 Weeks -Placebo
(n=60*)

Figure 1 Trial design and visit completion. *One participant from the Multivitamin group and one participant from the Placebo group failed
to provide qualitative data.

in the SMV group reported at least one positive experience compared to those in the placebo group (50.8%;
Table 5). In the area of positive reported effects, the
two main statistically significant themes identified in
the SMV group over the placebo group were an increase in energy and mental alertness, and an increase
in mood and mental/emotional wellbeing. More people
in the SMV group reported sleep improvement compared to placebo, but due to low power the result did
not reach statistical significance. Curiously, two participants reported a beneficial change in appetite, while
one person (placebo group) said their skin was better.
Of the negative effects reported, no significant differences were found between SMV and placebo (further
detail below).

reported experiences of increased energy and mental
alertness than females in the placebo group (22.5% difference). Positive perceived effects on participant’s energy levels commonly reported in the SMV group
included:

Multivitamin effects on energy levels

Multivitamin effects on mood and stress

A total of 17.2% more participants in the SMV group
significantly reported increased energy levels and mental
alertness compared to the placebo group (p =.022).
Females in the SMV group significantly (p =.020)

Compared with the placebo group, a total of 15.1% more
participants in the SMV group reported the experience
of better mood and emotional state. This difference was
statistically significant (p = .027). While nearly 20% more

“More alert, bright, full of energy”
“I found getting up early. . .easier”
“Have felt like I have more energy”
“I feel some sort of relaxation and energy”
“My energy levels were quite good over the period and
I felt happy most of the time”
“A general feeling of more alertness particularly in the
morning”
“I felt physically less tired”

Sarris et al. Nutrition Journal 2012, 11:110
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Table 3 Baseline characteristics of participants (n=114)*
Gender

Age

Education

Intelligence

BMI

Trait Anxiety

Depression

Male

30.93 (7.47)

17.00 (2.57)

28.43 (2.70)

26.13 (4.98)

31.00 (6.15)

3.82 (3.78)

Female

30.80 (6.46)

17.71 (3.14)

28.87 (2.25)

22.03 (5.59)

34.52 (7.84)

3.71 (4.04)

Total

30.86 (6.90)

17.37 (2.88)

28.66 (2.46)

23.98 (5.65)

32.85 (7.25)

3.76 (3.89)

Male

28.91 (6.90)

16.38 (1.86)

29.29 (3.18)

24.41 (3.21)

34.54 (9.43)

5.29 (4.67)

Female

32.94 (7.85)

17.71 (3.07)

28.13 (2.91)

23.98 (5.31)

32.68 (7.13)

4.61 (5.04)

Total

31.18 (7.76)

17.13 (2.67)

28.65 (3.06)

24.47 (4.46)

33.49 (8.18)

4.91 (4.85)

Male

30.00 (7.20)

16.71 (2.27)

28.83 (2.94)

25.34 (4.30)

32.63 (7.96)

4.50 (4.24)

Female

31.87 (7.21)

17.71 (3.08)

28.51 (2.60)

22.99 (5.50)

33.60 (7.49)

4.16 (4.56)

Total

31.02 (7.24)

17.25 (2.77)

28.65 (2.75)

24.07 (5.10)

33.16 (7.69)

4.32 (4.40)

Placebo

Multivitamin

All

* Data from participants randomized conditions; Data depicted as means and standard deviations; Education= Years of study; Intelligence = Matrix reasoning
score; Trait Anxiety = State-Trait Anxiety Inventory–Trait Scale Score; Depression = Beck Depression Inventory-II score.

female participants reported an improvement of mood
in the SMV compared to control, the result did not
reach significance (p =.054). Examples of beneficial
experiences reported by the SMV group in the area of
enhanced mood and reduced stress were:
“I feel a bit more carefree and I stress less”
“I have felt more relaxed; mood is more stable, less ups
and downs”
“Stress levels have reduced. . . Feel calmer”
“Mood more uplifted”
“Much more calm than before taking this”
“Mood-wise I think I am more patient”

Multivitamin effects on sleep

Another theme that emerged was the experience by some
participants of an improvement in their sleep. While 10%
more participants in the SMV group reported a positive effect on sleep, this was just outside of significance (p =.087).
Examples of beneficial effects in the SMV group:
“Less tired/easier to fall asleep"
“Sleep quite peaceful. . . Increased my sleep during the
night”
“Felt that tablets assisted in helping to sleep”
“Better sleep, less stress, more energy during the day
time”
Perceived negative experiences

Table 4 Experiential themes identified
Positive experience

Negative effect

Mental/Cognitive Domain
General Mental Benefit

Mental/Cognitive Domain
Impaired Concentration/Attention

Improved Concentration,
Attention &/or Memory

Stressed or Anxious

Increased Calmness or Relaxation

More Moody and Emotional

Better Mood & Emotional State

Physical Domain

Physical Domain

Impaired Sleep

General Physical Benefit

More Fatigued &/or Drowsy

Improved sleep

Poorer Health &/or Immunity

More Energetic &/or Alert

Upper Gastrointestinal complaint

Better Health &/or Immunity

Indigestion or Nausea

Dermatological Benefit

Dermatological Complaint

Increased/Better Appetite

Gynaecological Effect
Weight Gain

Importantly, no major adverse effects or reactions
emerged from our thematic analysis, providing additional support for the quantitative finding that SMV
was well tolerated by this sample. Overall SMV was
well-tolerated with no statistical difference in the number of overall negative effects reported between the placebo (28.8%) and MV (30.9%) groups. Negative mental
effects were not different between groups. Specifically,
three females reported feeling more ‘moody’ or ‘emotional’ compared to none in the placebo group. Five participants experienced impaired concentration/alertness
(two SMV, three placebo) three were more stressed or
anxious (two SMV, one placebo), however this was not
significantly different between groups.
Several participants reported experiencing mild negative physical reactions that occurred during the study.
The most common complaint related to participants
feeling dehydrated or need to drink soon after taking the
tablets; experiencing heartburn; or an unpleasant taste.
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Table 5 Differential positive and negative effects experienced by participants
Full sample

Positive experience

Males

Females

Placebo

Multi

Placebo

Multi

Placebo

Multi

n = 59

n = 55

n = 28

n = 24

n =31

n = 31

64.3%

62.5%

38.7%

58.1%

50.8%

60.0%

Mental/Cognitive Domain
General Mental Benefit

8.5%

9.1%

7.1%

0.0%

9.7%

16.1%

Improved Concentration, Attention &/or Memory

8.5%

9.1%

10.7%

20.8%

6.5%

0.0%

14.5%

Increased Calmness or Relaxation
Better Mood & Emotional State

20.3%

21.4%

25.0%

19.4%

6.5%

8.5%

23.6% *

7.1%

16.7%

9.7%

29.0% #

8.5%

5.5%

14.3%

12.5%

3.2%

0.0%

5.1%

15.5% #

3.6%

8.3%

6.5%

19.4%

11.9%

29.1% **

17.9%

29.2%

6.5%

29.0% ***

Physical Domain
General Physical Benefit
Improved Sleep
More Energetic &/or Alert
Better Health &/or Immunity

6.8%

10.9%

10.7%

8.3%

3.2%

12.9%

Dermatological Benefit

1.7%

0.0%

3.6%

0.0%

0.0%

0.0%

Increased/Better Appetite

1.7%

1.8%

3.6%

4.2%

0.0%

0.0%

28.8%

30.9%

25.0%

25.0%

32.3%

35.5%

Impaired Concentration/Attention

5.1%

3.6%

3.6%

4.2%

6.5%

3.2%

Stressed or Anxious

1.7%

3.6%

0.0%

0.0%

3.2%

6.5%

More Moody and Emotional

1.7%

5.5%

3.6%

0.0%

0.0%

9.7%

1.7%

1.8%

3.6%

0.0%

0.0%

3.2%

Negative experience
Mental/Cognitive Domain

Physical Domain
Impaired Sleep
More Fatigued &/or Drowsy

6.8%

5.5%

7.1%

8.3%

6.5%

3.2%

Poorer Health &/or Immunity

1.7%

1.8%

3.6%

0.0%

0.0%

3.2%

Upper Gastrointestinal complaint

1.7%

9.1%

0.0%

8.3%

3.2%

9.7%

Indigestion or Nausea

1.7%

3.6%

0.0%

4.2%

3.2%

3.2%

Dermatological Complaint

1.7%

1.8%

0.0%

4.2%

3.2%

0.0%

Gynaecological Effect

0.0%

3.6%

-

-

0.0%

6.5%

Weight Gain

3.4%

1.8%

3.6%

0.0%

3.2%

3.2%

*χ2(1)= 4.921, p = 0.027; ** χ2(1)= 5.245, p = 0.022; *** χ2(1) = 5.415, p = 0.020 #p = 0.05-0.10 (trend).

While 7% more participants in the SMV than the placebo group reported mild negative gastrointestinal
effects, this was just outside of statistical significance
(p=.077). Another negative experience included two
females in the SMV noting they had a negative gynaecological effect (one perceived an increase in premenstrual
symptoms, and the other a change in her menstrual
cycle). Two participants in the placebo group and one
participant in the multivitamin group reported weight
gain. Impaired sleep, dermatological complaints (rash or
dry skin/nails) and more frequent illness were each
reported by single participants in both groups.
Unusual experiences reported

Six unusual effects were reported by participants, although
it cannot be determined whether these experiences were

related to either group’s intervention. For the SMV group,
three unusual effects were reported: “Early on I felt that I
sweated more - under the arms” “Faeces more hard perhaps” “Sensitive to the room temperature when sleeping”.
A total of 3 people in the placebo group reported unusual effects: “I experienced fuzzy eyes” “Several mornings
I woke up with a headache” “Kidney-ache occurred for
the last six weeks. . . Quite intense about 4 weeks ago”.

Discussion
Results of the first exploratory qualitative assessment of
participants’ experiences of chronic daily administration
of a multivitamin (MV) revealed significant effects in
several areas. The major significant themes found
between SMV and placebo concerned participants’

Sarris et al. Nutrition Journal 2012, 11:110
http://www.nutritionj.com/content/11/1/110

perceived increased energy levels and enhanced mood,
with a trend towards some experiencing better
sleep. We performed a double-blind analysis and utilised
quantitative methods of data analysis (i.e. Chi square
test), increasing confidence in these results.
While assessment on quantitative numerical assessment scales is considered the “gold standard”, use of
qualitative methods, involving data from open-ended
questions, clinician’s notes, and forums, may reveal outcomes that may not have been found by established
quantitative assessment tools. This method has been
used successfully in other nutraceuticals studies [34,35],
but not yet for MV studies. As commented by Berk et al.
[35], unexpected but important phenomena may escape
detection in purely quantitative studies. In their doubleblind RCT involving the application of N-acetyl cysteine
for schizophrenia, emergent themes arose which had not
been captured by the quantitative rating scales utilised.
Such identified novel effects can potentially factor into
future practice guidelines, or can be specifically studied
in subsequent RCTs.
The finding of participants reporting significantly
increased mood and energy is in line with results of
previous MV and B vitamin complex research; adequate
B vitamin levels are critical for neuronal communication and energy generation. Importantly, very few participants experienced any negative effects, and no
significant adverse reactions were identified in the
study. The only cases of identified side effects concerned minor gastrointestinal symptoms; reactions such
as nausea have been previously reported by a small percentage of the general public who take a MV [36]. Analysis by gender revealed that the observed benefit on
mood and energy were more likely to be experienced
by women than men.
Limitations of the qualitative component are acknowledged. The use of a written semi-structured assessment
form does not provide the rich exploration of experience
that can achieved from interviews with open-ended
questions or focus groups, and the small sample size
meant that only very common effects of SMV could be
reliably detected. Additionally as the qualitative questions addressed perception of change due to treatment
they were only completed at the final testing visit. An
intent-to-treat analysis was therefore not possible for
this data and only study completers were included in the
analysis.
It should be noted that these analyses have not be corrected for multiple comparisons. When multiple outcome measures, such as our 21 themes, are assessed, a
p-value correction may not always be the best approach
as it can result in an overly conservative significance
level and increased likelihood of a Type 2 error [37]. The
themes seen here to benefit from multivitamin use are
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supported theoretically and by the supplementation
effects seen in previous quantitative studies.
The qualitative data presented here provides the first
exploration of the important topic of participants’
experiences and should prompt further, more in-depth
investigation of this topic as part of future RCTs.

Conclusions
This paper represents the first documented qualitative
investigation of participants’ experience of chronic administration of a multivitamin. Overall the exploratory
experiential data provided by the participants was
found to reflect the general findings of previous quantitative trial data; multivitamin supplementation may be
associated with appreciable mood enhancement and
increases in energy even in a normal, non-depressed
and non-anxious population. Future RCTs are encouraged to adopt a similar mixed-methods approach.
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